Michela Ceccolini

TL;DR: Thal-Dex may be considered an effective and relatively well-tolerated oral alternative to the more complex VAD regimen as front-line therapy for MM patients who are candidates for subsequent autologous transplantation.

TL;DR: MRI of the spine and pelvis still remains the gold standard imaging technique for the detection of bone marrow involvement in MM but 18F-FDG PET-CT provides additional and valuable information for the assessment of myeloma bone disease in areas not covered by MRI.

TL;DR: In comparison with TD, VTD effected significantly higher rates of response (≥partial response: 78.5% vs 92%, P), and the rate of complete response (CR)/near CR (nCR) following three 21-d cycles of induction therapy.

TL;DR: In May 2006, the Italian Myeloma Network GIMEMA initiated a multicenter, randomized phase III study comparing VTD with TD incorporated into ASCT for newly diagnosed MM, and 187 patients entered and 187 were evaluated for response to induction therapy and adverse events.

TL;DR: The association between osteonecrosis of the jaws and the use of bisphosphonates as therapy of neoplastic bone disease or benign osteoporosis is pointed out.